目的 探討屏風(fēng)生脈膠囊聯(lián)合沙美特羅替卡松氣霧劑治療支氣管哮喘的臨床療效。方法 選取2015年9月-2016年9月在杭州師范大學(xué)附屬醫(yī)院進(jìn)行治療的支氣管哮喘患者84例，根據(jù)治療方案的差別分為對照組（42例）和治療組（42例）。對照組吸入沙美特羅替卡松氣霧劑，1吸/次，2次/d。治療組在對照組的基礎(chǔ)上口服屏風(fēng)生脈膠囊，3粒/次，3次/d。兩組患者均治療4周。觀察兩組患者臨床療效，同時(shí)比較兩組患者治療前后臨床癥狀消失的時(shí)間、第1秒用力呼氣容積（FEV₁）、用力肺活量（FVC）、最大呼氣流速（PEF）等肺功能指標(biāo)、血清學(xué)指標(biāo)的變化。結(jié)果 治療后，對照組和治療組總有效率分別為80.95%、95.24%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者喘憋、咳嗽、肺部啰音消失的時(shí)間較對照組均顯著縮短，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者FEV₁、FVC、PEF均較同組治療前明顯升高，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組升高程度優(yōu)于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者血清IL-4、IL-6、TNF-α和NO水平明顯低于同組治療前，而IL-10、SOD水平明顯高于同組治療前（P<0.05）；且治療組上述指標(biāo)的改善程度更顯著（P<0.05）。結(jié)論 屏風(fēng)生脈膠囊聯(lián)合沙美特羅替卡松氣霧劑治療支氣管哮喘效果顯著，可有效改善患者臨床癥狀和肺功能，并可降低機(jī)體炎性反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma. Methods Patients (84 cases) with bronchial asthma in Hangzhou Normal University Affiliated Hospital from September 2015 to September 2016 were divided into control group (42 cases) and treatment group (42 cases) based on different treatments. Patients in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol, 1 suck/time, twice daily. Patients in the treatment group were po administered with Pingfeng Shengmai Capsules on the basis of the control group, 3 grain/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and clinical symptoms disappeared time, pulmonary function indexes FEV₁, FVC, and PEF and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 95.24%, respectively, and there were differences between two groups (P<0.05). After treatment, clinical symptoms disappeared time of wheezing, cough, and lung rale in two groups was decreased with significant difference between two groups (P<0.05). FEV₁, FVC, and PEF levels in two groups were increased, and there were significant differences between two groups before and after treatment (P<0.05). And the increase degree of FEV₁, FVC, and PEF levels in the treatment group was more significant than that in the control group (P<0.05). The levels of IL-4, IL-6, TNF-α, and NO in two groups were lower than those before treatment, while the levels of IL-10 and SOD were higher than those before treatment (P<0.05). And the improve degree of those indexes in the treatment group was more significant than that in the control group (P<0.05). Conclusion Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has a significant clinical effect in treatment of bronchial asthma, can improve clinical symptoms and pulmonary function, and decrease system inflammatory response, which has a certain clinical application value.